about
Rates of influenza vaccination in older adults and factors associated with vaccine use: a secondary analysis of the Canadian Study of Health and AgingApproved but non-funded vaccines: accessing individual protectionShort and long-term safety of the 2009 AS03-adjuvanted pandemic vaccineCanadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccinePandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adultsPre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt.Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.THE VAXED PROJECT: an assessment of immunization education in Canadian health professional programs.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Effects of a pharmacy-driven perisplenectomy vaccination program on vaccination rates and adherence to guidelinesInfluenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesImmune biomarkers predictive of respiratory viral infection in elderly nursing home residents.Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature.Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsA new approach to improving healthcare personnel influenza immunization programs: a randomized controlled trial.Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial.Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialThe challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers.Impact of pharmacists as immunizers on vaccination rates: A systematic review and meta-analysis.Parental intention to have daughters receive the human papillomavirus vaccine.Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know.Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada.Q fever update, Maritime CanadaImmunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenRandomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trialImpact of pharmacists as immunizers on influenza vaccination coverage in Nova Scotia, Canada.Routine immunization of adults by pharmacists: Attitudes and beliefs of the Canadian public and health care providers.Impact of pharmacists as immunizers on influenza vaccination coverage in the community-setting in Nova Scotia, Canada: 2013-2015.Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.CMKLR1 activation ex vivo does not increase proportionally to serum total chemerin in obese humans.Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
P50
Q24803408-C9B6064A-6B89-40F8-8BBC-14216B8B3686Q27022495-39CCD2CA-7771-41CF-8CB6-74ECAF5B4A74Q28727578-F6594A72-253F-451B-9909-A95063289295Q30388163-5B62AFE8-9C97-4BFE-8551-5E52759DB522Q30396846-9E66FA91-A1A5-467F-A0C7-9CDF0B4D2217Q30398400-8F56D487-177D-4FA6-8AEA-9A00B0E5E996Q30414902-B59D9108-0EE7-4C53-BE8C-F6F8AF5DFFB6Q30422975-9653CD4C-EA1D-43EE-AADA-1B3AC53B6478Q33573346-1CA5DA84-BF4C-461E-83F4-B861E5EA953EQ33713522-E041E2D5-540D-42B9-B78D-7AFC59E72361Q33756687-DC95EE9D-73EF-4549-9938-3BECEC2891C4Q33818337-FE4B7BE4-7B2B-490C-82CE-F074294C2285Q34125500-F2B5CB24-C738-413A-BF13-1DAB81A5FE5AQ34274845-6AC9F3F3-DD7A-4821-AD68-DBB6030A6E48Q34282272-2E718950-3641-4444-AE87-AC6FF5026456Q34342056-2CB8A4A2-FB0B-4F54-BE10-27B97721F1A8Q34635527-CC0D4F24-AFCC-4797-AC43-963FAD4209E8Q34738944-B0D97E4E-4261-473E-95FE-02FCDBA83ED7Q34778426-9D94CFC9-DB3A-46BB-A116-68B56F8C9AE4Q34999500-3A3E6F52-B735-4850-ABDD-1F2B8689C3B4Q35188288-8AF27032-41CF-4D65-B508-C29C875AE612Q35870407-64F9C312-CC85-47B4-8E0F-03169B9B691FQ36009631-AD16F2E2-2A4C-4A4E-99B5-6A984C3C599BQ36120473-19EFE1C6-CB55-4D69-90B1-5A531E4B023AQ36169950-0D083EEE-E43E-4285-8B9E-2C71DB832B9CQ36173657-308A7F42-091F-41BE-AC36-80A8795D4F6EQ36256236-C20B77AF-13BC-4E67-BCEA-5270F78E0A32Q36665657-4E14A827-66F2-4C71-B463-00C2EB7052EAQ36675963-610522B4-EA74-441B-8DA3-D4B72B35A10CQ36996715-63F9CD11-A031-4120-ADFB-95DB934F27A8Q37008902-CDF43011-FEE0-47D7-9452-F9A4D89F27F3Q37037095-A3FB8EB8-C72F-423B-A242-74033EB73622Q37118381-C0889DF4-6461-4197-8912-62B2C8AE0E2CQ37130808-87146169-0A09-4664-B600-35600BABAB52Q37131028-D78DCC49-FFB7-4814-A5A3-ED41B9F74DB0Q37135000-C95BBB4A-B426-4CDA-96A0-2A988F7CF7B8Q37349946-C876D636-5BCA-4129-B100-7AC8C815CDFBQ37405340-7495C3E5-ED8E-4026-B35F-0FB0518A92B4Q37490861-8F6391D5-BC7C-40C8-8041-E9030F62D339Q37560954-A4A931A9-1349-4D50-95CA-EA6410C5F481
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shelly A McNeil
@ast
Shelly A McNeil
@en
Shelly A McNeil
@es
Shelly A McNeil
@nl
type
label
Shelly A McNeil
@ast
Shelly A McNeil
@en
Shelly A McNeil
@es
Shelly A McNeil
@nl
prefLabel
Shelly A McNeil
@ast
Shelly A McNeil
@en
Shelly A McNeil
@es
Shelly A McNeil
@nl
P108
P106
P31
P496
0000-0001-5444-4166